Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Gyre Therapeutics Reported 2023 Revenue of $113.5M, Adj Net Income of $25.4M, Cash Balance of $33.5M

Author: Benzinga Newsdesk | March 26, 2024 06:07am

Posted In: GYRE